Thursday, March 5

PRE-Congress Workshops

12:45-14:15  First slot pre-congress workshops
14:45-16:15  Second slot pre-congress workshops

Nailfold Capillaroscopy - A Key Diagnostic Tool
Convenors: A Herrick (GB), M Cutolo (IT), V Smith (BE)

What is New on Ultrasound-Assessed Tissue Involvement in SSC
Convenor: E Naredo (ES)

Practical, Hands-on Workshop on How to Do the Modified Rodnan Skin Score
Convenor: D Furst (US), L. Czirjak (HU)

Digital Ulcer Management
Convenor: M Matucci-Cerinic (IT)

13:45-16:15 – one slot
Localized Scleroderma - New Approaches to Diagnosis and Therapy
Convenors: T Krieg (DE), P Moinzadeh (DE), J Stork (CZ)

16:30-17:30  Satellite Symposium Corbus Pharmaceuticals

17.30-18:00  Opening Ceremony

18:00-18:50  Opening Lectures
Chairpersons: D Furst (USA), T Krieg (D)
18:00-18:20  2-years in review: basic
C Feghali-Botswick (USA)
18:20-18:40  2-years in review: clinical
C Denton (UK)

18:40-19:10  WSF Projects
18:40-18:50  Development of the Optimal Touchscreen Interface for Patients with Scleroderma
G Moroncini et al (IT)
18:50-19:00  Randomized Controlled Trial of an Internet-Based Exercise Program to Improve Hand Function in Patients with Scleroderma: A Scleroderma Patient-Centered Intervention Network (SPIN) Study
L. Kwakkenbos et al (NL)
19:00-19:10  I’VE HANDED BACK MY MAN CARD*: EXPERIENCES, COPING STYLES, AND SUPPORT PREFERENCES OF MEN WITH SSC  
C Flurey et al (UK)

19:10-19:40  WSF honours Professor Kazuhiko Takehara for his career: Takehara’s prize  
Chairperson: K Takehara (JP)

19:20-19:30  UNRAVELLING THE AETIOPATHOGENESIS OF MORPHOEA BY NEXT GENERATION SEQUENCING OF PAIRED SKIN BIOPSIES  
AM Saracino et al (UK)

19:30-19:40  IMMUNIZATION OF MICE WITH HUMAN AT1R GENERATES AT1R-ACTIVATING ANTIBODIES AND INDUCES SSC-LIKE DISEASE  
F Petersen et al (DE)

19:45  Welcome Reception
Friday, March 6

08:00-09:20 SESSION 1 – PULMONARY
08:00-08:20 How to screen and follow up SSc-ILD?
   A Prasse (DE)
08:20-08:40 Group 3 PH, to treat or no to treat?
   S Gaine (IE)
08:40-08:50 COMPUTED TOMOGRAPHY-BASED RADIOMICS FEATURES FOR DETECTION AND STAGING OF INTERSTITIAL LUNG DISEASE IN SSc – TRANSFERABILITY FROM EXPERIMENTAL TO HUMAN LUNG FIBROSIS
   J Schniering et al (CH)
08:50-09:00 DISEASE COURSE OF PROGRESSIVE INTERSTITIAL LUNG DISEASE IN SSc: A 5-YEAR FOLLOW-UP FROM THE EUSTAR DATABASE
   A Hoffmann-Vold et al (NO)
09:00-09:10 NEW HEMODYNAMIC DEFINITIONS OF PULMONARY HYPERTENSION: IS IT USEFUL IN SSc PATIENTS?
   A Volkov et al (RU)
09:10-09:20 VEGF-C AND ITS RECEPTOR VEGFR-3 AS POTENTIAL SERUM BIOMARKERS FOR PULMONARY ARTERIAL HYPERTENSION IN SSc
   H Didriksen et al (NO)

09:25–10:35 SESSION 2 – HEART
09:25-09:45 Screening for myocardial disease in SSc: which tools and when?
   C Bucciarelli (UK)
09:45-10:05: Cardiac work-up in SSc: how to distinguish primary heart involvement from ordinary cardiovascular disease
   M Buch (UK)
10:05-10:15 SERUM CARDIAC BIOMARKERS AND CARDIAC MRI DIFFUSE FIBROSIS MAY PREDICT THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN SYSTEMIC SCLEROSIS PATIENTS
   B Dumitru Raluca et al (UK)
10:15-10:25 SSC MYOCARDITIS HAS UNIQUE CLINICAL, HISTOLOGICAL AND PROGNOSTIC FEATURES: COMPARATIVE ANALYSIS BETWEEN PATIENTS WITH ENDOMYOCARDIAL BIOPSY-PROVEN MYOCARDITIS
   G De Luca et al (IT)
10:25-10:35 PRIMARY SYSTEMIC SCLEROSIS HEART INVOLVEMENT (PSSCHI): A SYSTEMATIC LITERATURE REVIEW (SLR) AND PRELIMINARY CONSENSUS-BASED DEFINITION
   C Bruni et al (IT)

10:35-11:05 Coffee break

11:05-12:35 Satellite Symposium Actelion

12:35-13:40 Poster session and lunch

13:40-14:40 Satellite Symposium Boehringer Ingelheim

14:45-15:45 Satellite Symposium Merck

15:45-16:15 Coffee break
**SPECIAL SYMPOSIMUM**
Highlights in SSc research across journals: contribution from the recent literature

Chairpersons: M Kuwana (JP), A Clark (UK)

*Journal Scleroderma & Rel Dis*

16:15-16:35  Adipose-derived mesenchymal stromal/stem cells in systemic sclerosis: Alterations in function and beneficial effect on lung fibrosis are regulated by caveolin-1
S Hoffman (USA)

*Lancet Rheumatology*

16:35-16:55  Evidence-based consensus statements for the identification and management of interstitial lung disease in systemic sclerosis
A Hoffmann-Vold (NO)

*Lancet respiratory medicine*

16:55-17:15  Lung function preservation in a randomised placebo-controlled phase 3 trial of tocilizumab in systemic sclerosis
J van Laar (NL)

*Arthritis & Rheumatology*

17:15-17:35  The best highlights from A&R in 2019
J Varga (USA)

**HORIZON 2020**
The best from the Desscipher project

Chairperson: U Mueller Ladner (DE)

17:45-17:50  Introduction into the desscipher Project
U Mueller Ladner (DE)

17:50-18:00  Activity Indices and individualized Immunosuppression
V Lorand (H)

18:00-18:10  Functional Disability and Digital Ulcers
V Jaeger (DE)

18:10-18:15  Myocardium & Summary
U Mueller Ladner (DE)

**PARALLEL SESSION 3 - BASIC**

18:15-18:35  Can tissue transcriptome be used for patients stratification?
F Del Galdo (UK)

18:35-18:55  Update on circulating Biomarkers
M. Kuwana (JP)

18:55-19:05  MACHINE-LEARNING CLASSIFICATION IN THE ABATACEPT IN SYSTEMIC SCLEROSIS TRIAL (ASSET) IDENTIFIES A SUBSET OF PATIENTS THAT IMPROVE ON THERAPY VIA MODULATION OF A CD28-RELATED PATHWAY
M Whitfield et al (USA)

19:05-19:15  LARGE-SCALE EXAMINATION OF LONGITUDINAL SKIN GENE EXPRESSION AND ITS ASSOCIATIONS WITH SKIN THICKNESS IN SSC
B Skaug et al (USA)
19.15-19:25  SERUM INTERFERON SCORE PREDICTS WORSE CLINICAL OUTCOME AT 12 MONTHS IN DIFFUSE SSC AS MEASURED BY GLOBAL RANKED COMPOSITE SCORE (GRCS) AND ACR COMPOSITE RESPONSE INDEX IN SSC (CRISs)
F Del Galdo et al (UK)

19:25-19:35  INTERFERON CHEMOKINE SCORE PREDICTS RESPONSE TO TREATMENT IN SSC RELATED INTERSTITIAL LUNG DISEASE
S Assassi et al (USA)

18:15-19:15  PARALLEL SESSION 4 - VASCULAR
18:15-18:35  Updated Algorythm in managing DU including combination therapy
M Matucci-Cerinic (IT)

18:35-18:45  PERFORMANCE OF AUTOMATED NAILFOLD CAPILLARY COUNTING SYSTEM (AUTOCAPI) IN SSC PATIENTS
A Sulli et al (IT)

18:45-18:55  POTENTIAL BENEFICIAL EFFECTS FOR RESVERATROL IN SCLERODERMA VASCULOPATHY
B Kahaleh et al (USA)

18:55-19:05  ILOPROST USE AND MANAGEMENT OF SSC-RELATED VASCULOPATHY IN ITALIAN TERTIARY REFERRAL CENTERS: RESULTS FROM THE PROSIT STUDY
S Negrini et al (IT)

19:05-19:15  NAILFOLD CAPILLARY MICROSCOPY HAS LIMITED PROGNOSTIC VALUE IN PREDICTING FUTURE DEVELOPMENT OF CONNECTIVE TISSUE DISEASE IN CHILDREN WITH RAYNAUD’S PHENOMENON
G Van der Kamp et al (AN)

20:30  Congress Dinner
Saturday, March 7

08:00-09:00  MEET THE PROFESSOR SESSIONS
SRC - V Steen (USA)
Skin beyond fibrosis – T Krieg (DE)
How to interpret cardiac echo and right heart catheterism – C Bucciarelli (UK)
Difficult GI complications - SL Chatzinikolaou (UK)
How to manage early DcSSC – M Mayes (USA), J Pope (CA)

09:00-10:00  PARALLEL SESSION 5 – CLINICAL
09:00-09:10  PROVISIONAL AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) COMBINED RESPONSE INDEX IN DIFFUSE CUTANEOUS SSC (CRISS) SCORE CORRELATES WITH CHANGES <DELTA> IN PATIENT-REPORTED OUTCOMES (PRO)
R Spiera et al (USA)
09:10-09:20  THE EFFECT OF GENDER ON OUTCOME IN SSC: DOES ANTI-TOPOISOMERASE I AUTOANTIBODY (ATA) MATTER?
J De Vries-Bouwstra et al (NL)
09:20-09:30  THE PATIENT JOURNEY OF SSC-ILD IN EUROPE: AN INTEGRATED ANALYSIS OF HEALTHCARE PROFESSIONAL AND PATIENT PERSPECTIVES
A Hoffmann-Vold et al (NO)
09:30-09:40  THE TIMELINESS AND TYPES OF CANCER IN SSC
K Gunnarsson et al (SE)
09:40-09:50  THE RELATIONSHIP BETWEEN GASTROINTESTINAL SEVERITY AND SYMPTOMS AND WHOLE GUT TRANSIT IN PATIENTS WITH SSC
Z McMahan et al (USA)
09:50-10:00  VALIDATION OF DISEASE ACTIVITY MEASURES IN PATIENTS WITH JSSC – RESULTS FROM THE JSSC INCEPTION COHORT
I Foeldvari et al (DE)

09:00-10:00  PARALLEL SESSION 6 – BASIC
09:00-09:10  FGFR3/ FGF9 SIGNALING REGULATES A NETWORK OF PROFIBROTIC CYTOKINE AND GROWTH FACTOR PATHWAYS TO DRIVE FIBROBLAST ACTIVATION AND TISSUE FIBROSIS IN SSC
D Chakraborty et al (DE)
09:10-09:20  A NOVEL HUMANIZED MODEL FOR SSC BY TRANSFERRING PBMC FROM PATIENTS INTO IMMUNODEFICIENT MICE
X Yu et al (DE)
09:20-09:30  FLI1-DEFICIENT ADIPOCYTES PROMOTE SPONTANEOUS SKIN FIBROSIS AND VASCULOPATHY: POTENTIAL ROLES OF ADIPOCYTES IN SSC
T Miyagawa et al (JP)
09:30-09:40  ADENO-ASSOCIATED VIRUS-5 TARGETS PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA IN LUNG AND PERIPHERAL BLOOD OF PATIENTS WITH SYSTEMIC SCLEROSIS AND ELICITS STIMULATORY ANTIBODIES
G Moroncini et al (IT)
09:40-09:50  IMMUNE MECHANISMS OF DISORDER IN THE WORK OF THE BODY’S ANTIOXIDANT SYSTEM IN THE PATHOGENESIS OF LUNG DAMAGE IN SSC
L Shilova et al (RU)
09:50-10:00  TGFBRII-FC REDUCES FIBROSIS AND IMPROVES LUNG FUNCTION IN FOS-RELATED ANTIGEN-2 TRANSGENIC MICE, A MODEL OF SSC
G Li et al (USA)
10:00-10:30 The Debate: new treatments on the horizon
Nintedanib versus tocilizumab for treating SSc-ILD
O Distler (CH) vs D Khanna (USA)

10:30-11:00 Coffee break

11:00-12:20 SESSION 07 – SPECIAL ISSUES
11:00-11:20 SIBO: screening, diagnosis and treatment by a gastroenterologist
SL Chatzinikolaou (UK)
11:20-11:40 How imaging has improved the management of scleroderma in the last 10 years
M Vonk (NL)
11:40-12:00 The role of rehabilitation and exercising in the management of the various SSc manifestations
N Mugii (JP)
12.00-12.20 Vaccination of patients with autoimmune diseases: lights and shadows
P Bonanni (IT)

12:25–12:55 Satellite Symposium Sanofi

12:55-14:00 Poster session & lunch

14:00–14:30 Satellite Symposium CLS Behring

14:30-15:20 SESSION 8 – SKIN
Chairpersons: M Baron (CA), G Riemekasten (DE)
14:30-14:50 Outcomes regarding skin involvement: performance of mRSS and measurement of skin fibrosis beyond mRSS
J Pope (CA)
14:50-15:00 BIOSAMPLES FROM AT RISK SSC PATIENTS SHOW CLASSIC PATHOLOGICAL SIGNS OF SCLERODERMA: OPPORTUNITY FOR A DIAGNOSIS OF PRE-CLINICAL SSC
R Ross et al (UK)
15:00-15:10 OPTICAL COHERENCE TOMOGRAPHY OF THE SKIN DETECTS SCLERODERMA CHANGES IN CLINICALLY UNAFFECTED SKIN: AN OPPORTUNITY FOR EARLY DETECTION OF SSC
G Abignano et al (IT)
15:10-15:20 EXPLORING ASSOCIATION BETWEEN SKIN SCORE TRAJECTORY, SURVIVAL AND PULMONARY OUTCOME IN DIFFUSE CUTANEOUS SSC
S Nihtyanova et al (UK)

15:20-16:20 SESSION 9 – AUTOIMMUNITY FORUM
15:20-15:40 Why we develop overlapping autoimmune diseases
Y Shoenfeld (IL)
15:40-16:00 Antisynthetase syndrome
L Cavagna (IT)
16:00-16:20 Autoantibodies in interstitial lung disease and autoimmune rheumatic conditions
X Bossuyt (BE)
16:20-17:40  SESSION 10 - THERAPY

16:20-16:40  Progresses in the treatment of SSc - five examples from real life  
M Hinchcliff (USA)

16:40-16:50  DOES DOSE ADJUSTMENT AFFECT DECLINE IN FORCED VITAL CAPACITY IN PATIENTS TREATED WITH NINTEDANIB? DATA FROM THE SENSICS TRIAL (abs 235)  
M Mayes et al (USA)

16:50-17:00  INTENSIFIED IMMUNOSUPPRESSION COMBINED WITH PLASMAPHERESIS HAS FAVORABLE LONG TERM EFFECTS IN PATIENTS WITH EARLY-ONSET PROGRESSIVE SSc-INTERSTITIAL LUNG DISEASE (abs 177)  
J Potjewijd et al (NL)

17:00-17:10  RELATIONSHIP OF BASELINE MEASURES TO THE CHANGE IN THE FORCED VITAL CAPACITY IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL OF TOCILIZUMAB FOR THE TREATMENT OF EARLY SSC (abs 284)  
D Khanna et al (USA)

17:10-17:20  SAFETY AND EFFICACY OF ABATACEPT IN EARLY DIFFUSE CUTANEOUS SSC: RESULTS FROM THE OPEN-LABEL EXTENSION OF A PHASE II INVESTIGATOR-INITIATED RANDOMIZED CONTROLLED TRIAL (abs 427)  
L Chung et al (USA)

17:20-17:30  RISK FACTORS AND LONG-TERM FOLLOW UP OF PATIENTS WITH SYSTEMIC SCLEROSIS TREATED WITH OR WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE GERMAN NETWORK FOR SYSTEMIC SCLEROSIS (abs 469)  
N Blank et al (DE)

17:30-17:40  RIOCGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLEND, PLACEBO-CONTROLLED PHASE IIB STUDY (RISE-SSC) (abs 394)  
O Distler et al (CH)

17:40-18:00  HIGHLIGHTS OF THE CONGRESS  
J Varga (USA) & Y Allanore (FR)

18:00-18:15  CLOSURE OF THE CONGRESS